Pomaglumetad Effects on Glutamate Biomarkers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

95 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-31

Study Completion Date

2018-05-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will evaluate the effects of the mGluR2/3 partial agonist LY2140023 (Pomaglumetad Methionil, "POMA") at selected doses on ketamine-stimulated glutamate release in prefrontal cortex as measured by pharmacoBOLD fMRI (also termed resting BOLD fMRI).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarker Assessment of Glutamatergic Target Engagement

NCT02134951

Healthy Controls

COMPLETED PHASE4

Neural Biomarkers of Electroconvulsive Therapy Response

NCT04763655

Electroconvulsive Therapy Treated Patients

RECRUITING NA

MRS Measurement of Glutamate and GABA Metabolism in Brain

NCT00109174

Normal Physiology

RECRUITING NA

Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness

NCT01844726

Psychiatric Illness Healthy

TERMINATED PHASE2

Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN

NCT03341715

Familial Alcoholism Vulnerability

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study evaluates the effects of POMA at selected doses on ketamine-stimulated glutamate increase in the prefrontal cortex hypothesized to simulate the synaptic dysregulation that occurs endogenously in the pathogenesis of schizophrenia. The purpose of this is: 1) to determine whether the low dose (40 mg BID) utilized in recent (failed) clinical trials is sufficient to engage the primary target and 2) whether a higher (160 mg BID) dose, representing the maximum tolerated dose of POMA, engages the target to a greater degree. This study will further validate pharmacoBOLD as biomarker of mGluR2/3 target engagement, permitting its future use in other glutamatergic drug development.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Controls

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

POMA 40 mg BID

40 mg BID for 10 days

Group Type EXPERIMENTAL

POMA

Intervention Type DRUG

Pomaglumetad ("POMA") is a mGluR 2/3 partial agonist

POMA 160 mg BID

160 mg BID for 10 days

Group Type EXPERIMENTAL

POMA

Intervention Type DRUG

Pomaglumetad ("POMA") is a mGluR 2/3 partial agonist

Placebo

Placebo BID for 10 days

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

matching placebo tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

POMA

Pomaglumetad ("POMA") is a mGluR 2/3 partial agonist

Intervention Type DRUG

placebo

matching placebo tablets

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Pomaglumetad placebo comparator

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Medically healthy
* Capable of understanding the study procedures and able to provide informed consent
* Men and women must agree to use a reliable method of birth control during the study. Women who are post-menopausal or otherwise not of childbearing potential are also eligible

Exclusion Criteria

* Current or past Axis I psychiatric history
* Positive urine toxicology
* History of recreational ketamine use, recreational PCP use, or an adverse reaction to ketamine. Subjects who have participated in prior research ketamine studies will be eligible. Subjects can have infusions not more frequently than biweekly, and not more than 1/month on average, therefore subjects entering the study will need to wait one month if they had a single infusion and 6 weeks if they have had two closely spaced infusions.
* History of first-degree relative with schizophrenia
* History of violence
* Presence or positive history of significant medical illness
* Presence or positive history neurological illness or any other disease/procedure/accident/intervention association with significant injury to or malfunction of the central nervous system (CNS) or history of significant head injury
* Pregnancy or breast feeding
* Metal implants, pacemaker, other metal or paramagnetic objects contained within the body
* Medicinal patch, unless removed prior to MRI scan
* Currently taking any psychotropic medication, including antidepressant medications, benzodiazepines, antipsychotic medications, mood stabilizers, anti-epileptic medications and stimulants.
* Claustrophobia
* Suicidal ideation with intent or plan in the 6 months prior to screening
* Weight \> 86.95 kg (191.2 lbs)
* Subthreshold pharmacoBOLD response during screening ketamine infusion

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes